Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells $60,230.00 in Stock

Key Points

• Amneal Pharmaceuticals EVP Nikita Shah sold 6,340 shares at an average price of $9.50, totaling $60,230, which decreased their ownership by 4.15%.
• The company reported $0.23 earnings per share for the last quarter, exceeding analyst expectations of $0.17, while setting FY 2025 guidance at 0.700-0.750 EPS.
• Multiple hedge funds increased their stakes in Amneal, with Headlands Technologies boosting its stake by 570.1% in the last quarter.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Nikita Shah sold 6,340 shares of the company's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $9.50, for a total transaction of $60,230.00. Following the completion of the sale, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,390,828.50. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Nikita Shah also recently made the following trade(s):

• On Friday, August 22nd, Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.66, for a total transaction of $1,105,992.72.
• On Thursday, August 14th, Nikita Shah sold 71,694 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.29, for a total transaction of $666,037.26.
• On Tuesday, August 12th, Nikita Shah sold 50,000 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.04, for a total transaction of $452,000.00.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX traded down $0.31 during mid-day trading on Monday, reaching $9.28. 1,111,483 shares of the company's stock traded hands, compared to its average volume of 1,684,684. The stock has a market cap of $2.91 billion, a P/E ratio of 928.93 and a beta of 1.11. The business has a 50-day simple moving average of $8.38 and a 200 day simple moving average of $8.01. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.68 and a 1-year high of $9.79.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC boosted its stake in shares of Amneal Pharmaceuticals by 570.1% in the 2nd quarter. Headlands Technologies LLC now owns 24,692 shares of the company's stock valued at $200,000 after purchasing an additional 21,007 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Amneal Pharmaceuticals by 510.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,768 shares of the company's stock valued at $144,000 after purchasing an additional 14,855 shares in the last quarter. State of Tennessee Department of Treasury purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $133,000. Voleon Capital Management LP boosted its stake in shares of Amneal Pharmaceuticals by 33.8% in the 2nd quarter. Voleon Capital Management LP now owns 62,065 shares of the company's stock valued at $502,000 after purchasing an additional 15,677 shares in the last quarter. Finally, Rafferty Asset Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 22.0% in the 2nd quarter. Rafferty Asset Management LLC now owns 16,984 shares of the company's stock valued at $137,000 after purchasing an additional 3,066 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Wall Street Zen lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on shares of Amneal Pharmaceuticals in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $11.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.